Singapore - English - HSA (Health Sciences Authority)

dksh singapore pte. ltd. - live attenuated mycobacterium bovis (bcg) danish 1331 - injection, powder, for solution - 0.75 mg/ml - live attenuated mycobacterium bovis (bcg) danish 1331 0.75 mg/ml

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

serum institute of india pvt. ltd. - bcg vaccine(bacillus calmette guerin strain) - powder lyophilized for solution for injection - between 2x10^5 and 8x10^5 cfu/0,1ml

Ireland - English - HPRA (Health Products Regulatory Authority)

medac gesellschaft für klinische spezialpräparate mbh - bacillus calmette guérin (bcg) - powder and solvent for intravesical suspension - unknown - other immunostimulants; bcg vaccine

United Kingdom - English - VMD (Veterinary Medicines Directorate)

animal and plant health agency - mycobacterium bovis subsp. bovis - lyophilisate and solvent for suspension for injection - live bacterial vaccine - badger

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - mycobacterium bovis (bacillus calmette and guerin (bcg) strain), quantity: 200000000 cfu - injection, powder for - excipient ingredients: citric acid monohydrate; ferric ammonium citrate; strong ammonia solution; purified water; asparagine; magnesium sulfate heptahydrate; zinc formate dihydrate; lactose monohydrate; dibasic potassium phosphate; glycerol - onco tice is used as a treatment of primary or recurrent carcinomain situ of the urinary bladder. onco tice is also used after transurethral resection for the prevention or recurrence of high grade and/or relapsing superficial papillary transitional cell carcinoma of the urinary bladder (viz papillary carcinoma stage ta or t1 - grades 1, 2, or 3) indications as at 3 october 2001: oncotice is used as a treatment ofthe urinary bladder. oncotice is also used after transurethral resection for the prevention of recurrence of high grade and/or relapsing superficial papillary transitional cell carinoma of the urinary bladder (viz papillary carcinoma stage ta (grade 2 or 3) or t1 (grade 1, 2, or 3). oncotice is only recommended for stage ta grade 1 tumours, when there is judged to be a high risk of tumour recurrence is considered likely. inidications as at 24 april 2002: oncotice is used as a treatment of primary of recurrent carcinoma in situ (cid) of the urinary bladder. oncotice is also used after transurethral resection for the prevention of recurrence of high grade and/or relapsing superficial papillary transitional cell carcinoma of the urinary bladder (viz papillary carcinoma stage ta (grade 2 or 3) or t1 (grade 1, 2, or 3). oncotice is only reccommended for stage ta grade 1 tumours, when there is judged to be a high risk of tumour recurrence.

Israel - English - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - bcg strain - powder for solution for instillation - bcg strain 200 - 800 miu - bcg vaccine - bcg vaccine - oncotice is used as a treatment of flat urothelial cell carcinoma in situ (cis) of the bladder and as an adjuvant therapy after transurethral resection (tur) of a primary or relapsing superficial papillary urothelial cell carcinoma of the bladder stage ta (grade 2 or 3) or t1 (grade 1 2 or 3). oncotice is only recommended for stage ta grade 1 papillary tumors when there is judged to be a high risk of tumor recurrence.

United States - English - NLM (National Library of Medicine)

merck sharp & dohme llc - bacillus calmette-guerin substrain tice live antigen (unii: 2xq558l16z) (bacillus calmette-guerin substrain tice live antigen - unii:2xq558l16z) - bacillus calmette-guerin substrain tice live antigen 50 mg - bcg vaccine (tice® strain) is indicated for the prevention of tuberculosis in persons not previously infected with m. tuberculosis who are at high risk for exposure. as with any vaccine, immunization with bcg vaccine may not protect 100% of susceptible individuals. the advisory committee on immunization practices (acip) and the advisory committee for the elimination of tuberculosis has recommended that bcg vaccination be considered in the following circumstances.{3} bcg vaccination is recommended for infants and children with negative tuberculin skin tests who are (a) at high risk of intimate and prolonged exposure to persistently untreated or ineffectively treated patients with infectious pulmonary tuberculosis and who cannot be removed from the source of exposure and cannot be placed on long-term primary preventive therapy, or (b) continuously exposed to persons with infectious pulmonary tuberculosis who have bacilli resistant to isoniazid and rifampin, and the child cannot be separated from the presence of the infectious patient.{3} bcg vaccination of hcws should be considered on an individual basis in settings where (a) a high percentage of tb patients are infected with m. tuberculosis strains resistant to both isoniazid and rifampin, (b) transmission of such drug resistant m. tuberculosis strains to hcws and subsequent infection are likely, and (c) comprehensive tb infection control precautions have been implemented and have not been successful. vaccination should not be required for employment or for assignment of hcws in specific work areas. hcws considered for bcg vaccination should be counseled regarding the risks and benefits associated with both bcg vaccinations and tb preventive therapy.{3} bcg vaccination is not recommended for hcws in settings in which the risk for m. tuberculosis transmission is low.{3} bcg vaccine for prevention of tuberculosis should not be given to persons (a) whose immunologic responses are impaired because of hiv infections, congenital immunodeficiency such as chronic granulomatous disease or interferon gamma receptor deficiency, leukemia, lymphoma, or generalized malignancy or (b) whose immunologic responses have been suppressed by steroids, alkylating agents, antimetabolites, or radiation.{3} bcg vaccine should not be administered to hiv-infected or immunocompromised infants, children, or adults. prior to administration, the possibility of allergic reactions should be assessed. allergy to any component of bcg vaccine or an anaphylactic or allergic reaction to a previous dose of bcg vaccine are contraindications for vaccination. bcg vaccine is not a vaccine for the treatment of active tuberculosis. bcg vaccine should not be used in infants, children, or adults with severe immune deficiency syndromes. children with a family history of immune deficiency disease should not be vaccinated; if they are, an infectious disease specialist should be consulted and anti-tuberculous therapy administered if clinically indicated.{18} please read this leaflet carefully before administering bcg vaccine. the vaccine is to be administered after fully explaining the risks and benefits to the vaccinee, parent, or guardian. bcg vaccination should not be given to individuals previously infected with m. tuberculosis. the sterile, single-use multiple puncture device is for use with the bcg vaccine only. figure 1 figure 2 figure 5 caution: federal law restricts this device to sale by or on the order of a physician. multiple puncture devices may be obtained separately from the order management center, merck sharp & dohme llc, 351 north sumneytown pike, north wales, pa 19454-2505, telephone number: 800-637-2579.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

radiantaire sdn bhd - bcg live -

United States - English - NLM (National Library of Medicine)

uspharmaco - mycobacterium phlei (unii: t67520t45f) (mycobacterium phlei - unii:t67520t45f) - mycobacterium phlei 6 [hp_x] in 5 ml - for temporary relief of cold / flu symptoms

United States - English - NLM (National Library of Medicine)

sanum kehlbeck gmbh & co. kg - mycobacterium microti immunoserum rabbit (unii: 3zqn4y38qi) (mycobacterium microti immunoserum rabbit - unii:3zqn4y38qi), mycobacterium bovis immunoserum rabbit (unii: nnw4543crp) (mycobacterium bovis immunoserum rabbit - unii:nnw4543crp), streptococcus pyogenes immunoserum rabbit (unii: 726rs6qms8) (streptococcus pyogenes immunoserum rabbit - unii:726rs6qms8) - mycobacterium microti immunoserum rabbit 9 [hp_x] in 10 ml - homeopathic medicine 0.34 fl oz (10 ml) headache and arthritis/rheumatism pain.